The murine thigh infection model is a gold standard in preclinical antimicrobial research. It provides a robust and reproducible system to study bacterial and fungal infections in muscle tissue, making it particularly valuable for efficacy studies. This model has been extensively used for antibiotic development and is widely accepted by regulatory agencies as a translational tool to support dose selection and clinical trial design.

Septicemia, also known as bloodstream infection or sepsis, is one of the leading causes of mortality worldwide and a major clinical challenge. It results from the systemic spread of pathogens and triggers a dysregulated immune response, often leading to septic shock and multi-organ failure. The increasing incidence of multidrug-resistant bacteria and the high mortality associated with fungal sepsis underscore the urgent need for novel therapeutic approaches.

Gastrointestinal (GI) infections represent a critical global health burden. They are a major cause of morbidity and mortality, particularly among children, elderly individuals, and immunocompromised patients. The increasing prevalence of antimicrobial resistance, recurrent hospital-acquired GI infections, and limited therapeutic options highlight the urgent need for innovative approaches.

Urinary tract infections (UTIs) are among the most common bacterial infections worldwide, affecting millions of patients every year. They are a major cause of morbidity, recurrence, and healthcare costs, particularly in women, elderly individuals, and hospitalized patients with catheter-associated UTIs. The growing incidence of multidrug-resistant Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecium poses a serious threat, making the development of new therapeutic approaches an urgent priority.

Pulmonary infections remain a major global health challenge. They are responsible for significant morbidity and mortality and represent one of the leading causes of hospitalization worldwide. The rise of antimicrobial resistance, the emergence of new respiratory pathogens, and the limited number of effective treatments highlight the urgent need for innovative therapies.